Dr. Curti was a Senior Investigator at the National Cancer Institute and was an Associate Professor at the Penn State College of Medicine before joining Providence Cancer Center and Earle A. Chiles Research Institute as the Director of Genitourinary Oncology Research and the Immunotherapy Clinical Program, and Co-Director of the Melanoma Program.
His research and clinical interests involve developing vaccines and other novel immune-based treatments for prostate cancer, kidney cancer and melanoma.
Dr. Brendan Curti is a graduate of Georgetown University School of Medicine. He completed an internal medicine residency at Penn State College of Medicine and an oncology fellowship at Georgetown.
Prostate cancer immunotherapy moves forward
Ipilimumab among treatment advances for metastatic melanoma
Advances in prostate cancer immunotherapy at Providence
Therapy seeks to break melanoma's grip, Providence inScope
Clinical trial offers great hope for metastatic melanoma patients
Helping the immune system eliminate cancer with targeted radiation, The Oregonian
Life after melanoma, Providence eTogether News
Bringing out the big guns to kill cancer
Outcomes promising in OX40 study at Providence Cancer Center, The Oregonian
Find a full list of Dr. Curti's publications